Tazarotene
Spezifikationen
118292-40-3CAS-Nummer
ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylateIUPAC-Name
C21H21NO2SChemische Formel
351.5 g/molMolekulargewicht
tazarotene; 118292-40-3; Tazorac; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Zorac; Avage; AGN-190168; Fabior; tazaroteno; tazarotenum; DTXSID5046691; Idp-123; 81BDR9Y8PS; AGN190168; ARAZLO; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; DTXCID3026691; CHEBI:32184; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; DUOBRII COMPONENT TAZAROTENE; ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate; ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate; Tazaratone; Tazarodex; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate; ethyl 6-(2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl)pyridine-3-carboxylate; ethyl 6-(2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl)pyridine-3-carboxylate; PSO THERA; RefChem:58033; PSO THERA Scalp Psoriasis; D05AX05; Tazarodex Plaque Psoriasis and Acne; 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-3-Pyridinecarboxylic Acid, Ethyl Ester; 601-516-4; AGN 190168; C21H21NO2S; Tazarotene (Avage); MFCD00867628; Tazarotene-d8; CHEMBL1657; NCGC00167525-01; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Suretin; Tazoral; Zora; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; Tazorac (TN); Avage (TN); CAS-118292-40-3; 1246815-76-8; UNII-81BDR9Y8PS; Acnitaz; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate; Tazarotene (JAN/USAN/INN); Tazarotene [USAN:INN:BAN]; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate; Fabior (TN); Tazarotene (Standard); TAZAROTENE [MI]; TAZAROTENE [INN]; TAZAROTENE [JAN]; TAZAROTENE [USAN]; TAZAROTENE [VANDF]; SCHEMBL3134; TAZAROTENE [MART.]; TAZAROTENE [WHO-DD]; MLS003915630; BIDD:GT0293; GTPL6952; orb1226860; orb1300547; orb3025051; Tazarotene - Bio-X trade mark; SCHEMBL29397163; SCHEMBL29512592; TAZAROTENE [ORANGE BOOK]; HMS3655K05; HMS3747C19; HMS3747E19; HMS5079G16; MSK10233; WZB81576; Tox21 112522; Tox21_112522; 6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; AC-755; BDBM50265951; EBC-11242; HY-15388R; s1569; IDP-118 COMPONENT TAZAROTENE; AKOS015902872; Tox21_112522_1; BS-1012; CCG-268046; DB00799; FT28011; NCGC00167525-02; NCGC00167525-03; NCGC00167525-09; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; BT164442; HY-15388; SMR002096194; SY053169; DB-014992; NS00006771; SW220026-1; T6696; D01132; AB01274801-01; AB01274801_02; F093378; SR-01000931253; Q3981685; SR-01000931253-2; BRD-K76841105-001-04-7; Z1424590960; 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester; 6-(2-(4,4-dimethyl-thiochroman-6yl)ethynyl)-nicotinic acid ethyl ester; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylesterSynonyme
